CPT code 86485 represents a laboratory assay that evaluates a patient’s immunological response to a candida skin injection, used to assess cell-mediated immunity and delayed-type hypersensitivity. The code is nationally relevant for clinicians managing patients with suspected immune dysfunction, pre-transplant evaluations, or monitoring of immunosuppressive therapy where cutaneous antigen challenge informs clinical decision-making.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines coverage patterns and reimbursement considerations among these major payers and summarizes typical sites of service and clinical contexts where the test is ordered.

Readers will learn the clinical purpose of CPT code 86485, typical settings where the test is performed, and what information the code captures for billing and administrative workflows. The report provides benchmarking context, common billing modifiers encountered with this test (listing provided separately), and notes on documentation elements that support coding and claims submission. Data not available in the input is noted where applicable.